NasdaqGS:GHHealthcare
Assessing Guardant Health (GH) Valuation After New Colon Cancer ctDNA Study Publication
Why this new colon cancer study matters for Guardant Health (GH)
Guardant Health (GH) is back in focus after publishing, with Mayo Clinic and the Alliance for Clinical Trials in Oncology, the largest study so far using its Guardant Reveal blood test in resected stage III colon cancer.
The Journal of Clinical Oncology paper reports that Guardant Reveal detected circulating tumor DNA in about 20% of more than 2,000 patients after surgery, identifying a group with a four to six times higher rate...